| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Abacavir | Abacavir 5’-Phosphate | VL760020 | View CAS 136470-77-4 |
| Abacavir | Abacavir Carboxylate | VL760021 | View CAS 384380-52-3 |
| Abacavir | Abacavir Cyclopropyl Diamino Purine Impurity | VL760002 | View CAS 120503-69-7 |
| Abacavir | Abacavir EP Impurity A | VL760013 | View CAS 136470-79-6 |
| Abacavir | Abacavir EP Impurity B | VL760001 | View CAS 1443421-69-9 |
| Abacavir | Abacavir EP Impurity C | VL760006 | View CAS 124752-25-6 |
| Abacavir | Abacavir EP Impurity D (Free Base) | VE0010465 | View CAS 783292-37-5 |
| Abacavir | Abacavir EP Impurity D (HCl Salt) | VL760005 | View CAS 267668-71-3 |
| Abacavir | Abacavir EP Impurity E | VL760014 | View CAS 208762-35-0 |
| Abacavir | Abacavir EP Impurity F | VL760003 | View CAS 1443421-68-8 |
| Abacavir | Abacavir Ethanolate Impurity | VL760004 | View |
| Abacavir | Abacavir Impurity 1 | VL760011 | View CAS 2022943-79-7 |
| Abacavir | Abacavir Impurity 4 | VL760015 | View |
| Abacavir | Abacavir Impurity 5 | VL760016 | View |
| Abacavir | Abacavir Impurity 6 | VL760017 | View |
| Abacavir | Abacavir Methanolate Impurity | VE008660 | View |
| Abacavir | Abacavir N-Oxide Impurity | VL760010 | View CAS 1443421-70-2 |
| Abacavir | Abacavir Related Compound B | VL760025 | View CAS 141271-12-7 |
| Abacavir | Abacavir Related Compound C | VL760026 | View CAS 172015-79-1 |
| Abacavir | Abacavir-1-O-pyrimidine Derivative | VE008692 | View |
| Abacavir | Abacavir-5'-glucuronide | VL760019 | View CAS 384329-76-4 |
| Abacavir | Avermectin B1a Monosaccharide | VL4970010 | View CAS 71831-09-9 |
| Abacavir | Clorabacavir Racemic | VL760012 | View CAS 1918156-05-4 |
| Abacavir | Decitabine Urea Impurity | VL760027 | View CAS 570410-72-9 |
| Abacavir | N-(4-(hydroxymethyl)cyclopent-2-enyl)acetamide | VE009166 | View |
| Abacavir | Prucalopride-N-Galactopyranoside | VL760028 | View |
| Abacavir | Trans - Aminocarbinol | VE008534 | View |
| Abacavir | 3 Hydroxy Abacavir | VL760008 | View |
| Abacavir | ((1S, 4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl)methyl formate | VE009171 | View |
Abacavir Related Compound
Abacavir is used in the treatment of human immunodeficiency virus (HIV) infection in combination with other drugs.
References
- “Abacavir (Ziagen): Basics, Side Effects & Reviews.” GoodRx, 28 Nov. 2020, www.goodrx.com/abacavir/what-is.
- Yuen, Geoffrey J., et al. “A Review of the Pharmacokinetics of Abacavir.” Clinical Pharmacokinetics, vol. 47, no. 6, 2008, pp. 351–71, https://doi.org/10.2165/00003088 200847060-00001.
- Ma, Joseph D., et al. “HLA-B*5701 Testing to Predict Abacavir Hypersensitivity.” PLoS Currents, vol. 2, Dec. 2010, p. RRN1203, https://doi.org/10.1371/currents.rrn1203.
FAQ’s
What is the generic name of abacavir?
Abacavir (Ziagen) is a reverse transcriptase inhibitor containing nucleosides (NRTI).
What is abacavir's half-life?
Abacavir has a terminal elimination half-life of around 1.5 hours. The antiviral activity of abacavir is related to its intracellular anabolite, carbovir-triphosphate (CBV-TP).
Does abacavir cause hypersensitivity?
Abacavir can cause a treatment-limiting hypersensitivity response, which can be severe and potentially lethal.
